Winners & Losers
Health stocks were stagnant at the start of the week as investors digested a regulatory letter affecting one stock and an upcoming advisory panel that will affect another. The Nasdaq and Amex biotechnology indices were down less than half a percentage point Monday, while the Amex Pharmaceutical index lagged 0.7%, at 304.67. Big Pharma stocks and components of the Amex index, GlaxoSmithKline GSK, Eli Lilly LLY and Wyeth WYE, were all down more than 1%. On the advancing side, Discovery Labs DSCO shares gained 31.7% to $1.91 Monday, recovering some of the ground lost Friday when news of regulatory delays hit the stock hard. The company said Monday it believes it will not need more clinical trials to gain Food and Drug Administration approval for its thrice-brushed off infant lung drug Surfaxin. Meanwhile, investors weighed sentiment on Cephalon CEPH, a day before an FDA advisory panel is set to meet to discuss expanded use of the company's pain drug Fentora. Lehman Brothers analyst Jim Birchenough lowered his price target for the stock to $88 from $93, ahead of the panel meeting. Overall, Wall Street analysts were mixed about the mood and likely outcome of the panel, which will discuss ramifications of expanded approval of the pain drug, including a potential increase in its abuse. Shares edged down 46 cents, or 0.8%, to $60.12 Monday In earnings, Albany Molecular AMRI said first-quarter revenue increased 11% to $53.6 million. The research services firm reported adjusted profit of $4.7 million, or 15 cents a share, up from $3.1 million, or 10 cents a share, a year ago. Analysts surveyed by Thomson Financial were looking for earnings of 3 cents a share on revenue of $47.6 million. Shares added $1.83, or 16%, to $13.30.
Discovery Labs falls on another regulatory delay for its Surflaxin.
PharmaNet swings to a loss and slides.
BioMarin climbs higher after swinging to a profit and beating Wall Street estimates for the first quarter.
Apple and AT&T were among the most searched stocks on TheStreet.com Friday. Here's what Cramer had to say about them recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Looking for deep value with Defiance Asset Management, polling big investors about where the market's headed, plus much more.
See who made what calls.
3 Stocks I Saw On TVDan Fitzpatrick examines three stocks viewed on Fast Money and Mad Money Today's stocks include Deere & Co., Petrobras and MBIA
TheStreet.com Ratings checks in on First Community Bancorp and First Niagara Financial Group two months after recommending the stock.
Take-Two's latest hit receives a perfect score from industry reviewers.
- Cramer's 'Mad Money' Recap: Mad Money's Rally Playbook
- The Polycarbonate Price Cut
- CalPERS Pushes for Clean House at Standard Pacific
- Investing in China: What You Need to Know
- Coming Week: 'Glimmer of Hope'
- Top Stocks With Insider Buying, Buybacks
- New Solar ETF Helps Spread Sector's Risk
- Feuerstein's Biotech-Stock Mailbag
- Need to Own Energy? Here's How to Do It
- My Company Doesn't Provide Health Insurance (Gulp!)
Sponsored by:

BEAT THE STREET GAME:



